Clinical trial results:
An Open Label Multi-Centre Preoperative Window of Opportunity Study of Afatinib in Stage Ia to IIb Non-Small Cell Lung Cancer

Summary

EudraCT number	2012-004537-16
Trial protocol	GB
Global end of trial date	01 August 2016

Results information

Result version number	v1 (current)
This version publication date	28 December 2019
First version publication date	28 December 2019
Summary attachment (see zip file)	ABLE Termination Documentation (ABLE Endo of Trial Documentation MHRA 15Aug16.pdf)

Trial information

Trial identification

Sponsor protocol code	MO11/10085

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	University of Leeds
Sponsor organisation address	Worsley Building, Leeds, United Kingdom, LS2 9JT
Public contact	Dr Clive Mulatero, University of Leeds, 0113 2068650, clive.mulatero@leedsth.nhs.uk
Scientific contact	Dr Clive Mulatero, University of Leeds, 0113 2068650, clive.mulatero@leedsth.nhs.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 August 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 August 2016
Global end of trial reached?	Yes
Global end of trial date	01 August 2016
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The principal research question is whether a reduction in the amount of energy the cancer uses can be seen when a short course of afatinib is given to early stage lung cancer patients before surgery?

Protection of trial subjects:

To assess safety and tolerability of preoperative afatinib was a secondary objective of the trial. The Trial was overseen by a Independent Data Monitoring committee and trial steering committee, was monitored by the Sponsor twice over it's life cycle, and was conducted in accordance with GCP. Each PI retains overall responsibility for the informed consent of participants at their site and must ensure that any person delegated responsibility to participate in the informed consent process is duly authorised, trained and competent to participate according to the ethically approved protocol,principles of Good Clinical Practice (GCP) and Declaration of Helsinki 1996.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 January 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 7
Worldwide total number of subjects	7
EEA total number of subjects	7

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4
From 65 to 84 years	3

85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants will be recruited from NHS hospitals in the UK. The annual recruitment target is 40 participants per year.Recruitment will be competitive between participating centres. Up to 69 eligible patients may be recruited in order that a total of 59 patients will complete the protocol specified treatment.

Pre-assignment

Screening details:

Once written informed consent has been obtained and the participant has been registered, they must then be formally assessed for eligibility prior to commencing treatment.Patients identified as not eligible for trial treatment through eligibility screening will not be considered enrolled in the trial and will return to standard clinical care.

Period 1

Period 1 title	Main Trial Period (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Baseline Arm

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Afatinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Afatinib (BIBW2992) at a dose of 50mg orally will be administered daily for at least two weeks prior to surgery and for a maximum of thirty days.

Arm title	End Data

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Afatinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Afatinib (BIBW2992) at a dose of 50mg orally will be administered daily for at least two weeks prior to surgery and for a maximum of thirty days.

Number of subjects in period 1	Baseline Arm	End Data
Started	1	6
Completed	1	6

Baseline characteristics

Reporting groups	
Reporting group title	Main Trial Period

Reporting group description: -

Reporting group values	Main Trial Period	Total	
Number of subjects	7	7	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	4	4	
From 65-84 years	3	3	
85 years and over	0	0	
Gender categorical Units: Subjects			
Female	2	2	
Male	5	5	

End points

End points reporting groups

Reporting group title	Baseline Arm
Reporting group description: -	
Reporting group title	End Data
Reporting group description: -	

Primary: prospectively evaluate whether changes in SUVmax can be observed with 18F-FDG PET/CT imaging after only two weeks of afatinib (BIBW2992) therapy.

End point title	prospectively evaluate whether changes in SUVmax can be observed with 18F-FDG PET/CT imaging after only two weeks of afatinib (BIBW2992) therapy.[1][2]
End point description:	
End point type	Primary
End point timeframe:	
after two weeks of afatinib (BIBW2992) therapy.	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The trial was terminated early and no data was collected on participants.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The trial was terminated early and no data was collected on participants.

End point values	End Data			
Subject group type	Reporting group			
Number of subjects analysed	0[3]			
Units: SUVmax				
number (not applicable)				

Notes:

[3] - The trial was terminated early and no data was collected on participants.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]

Timeframe for reporting adverse events:

Adverse events will be collected for all participants from the time of written informed consent until 30 days post cessation of trial therapy.All AEs will be monitored until resolution, or if the AE is determined to be chronic, until a cause is identified

Assessment type	Systematic

Dictionary used

Dictionary name	CTCAE
Dictionary version	4.0

Reporting groups

Reporting group title	Baseline Arm
Reporting group description: -	
Reporting group title	End Data
Reporting group description: -	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: The trial was terminated early and no data was collected on participants.

Serious adverse events	Baseline Arm	End Data	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)	1 / 6 (16.67%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Blood and lymphatic system disorders			
Chyle Leak	Additional description: Event was reported as a SUSAR		
subjects affected / exposed	0 / 1 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Baseline Arm	End Data	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)	0 / 6 (0.00%)	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 March 2013	Protocol version 4.0 dated 1st March 2013 Main PIS and consent version 4.0 dated 1st March 2013 GP letter version 4.0 dated 1st March 2013 Revised label version 4.0 Investigator Brochure version 13 dated 11 July 2012
16 April 2013	Protocol version 5.0 dated 11 April 2013
29 November 2013	Protocol version 6.2 dated 25 November 2013 Main patient information sheet and consent version 6.0 dated 25 November 2013 Patient information sheet and consent version 3.0 dated 9 May 2013 GP letter version 5.1 dated 25 November 2013 Diary card version 3.0 dated 27 September 2013
18 December 2014	Protocol v 7.0
16 March 2016	Protocol version 8.0, Amendment 6, 27 January16 March 2016 PIS version 7.0, 27 January 2016 GP Letter version 6.0, 27 January 2016

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported